Ruxolitinib does not impair humoral immune response to COVID-19 vaccination with BNT162b2 mRNA COVID-19 vaccine in patients with myelofibrosis
Giovanni Caocci, Olga Mulas, Daniela Mantovani, Alessandro Nanni Costa, Andrea Galizia, Luca Barabino, Marianna Greco, Roberta Murru, Giorgio La Nasa
Topics & Concepts
RuxolitinibMedicineMyelofibrosisVaccinationMyeloproliferative neoplasmImmunologyCytopeniaHematologyInternal medicineBone marrowMyeloproliferative Neoplasms: Diagnosis and TreatmentAutoimmune and Inflammatory Disorders ResearchChronic Myeloid Leukemia Treatments